title: L-652,469--a dual receptor antagonist of platelet activating factor and dihydropyridines from Tussilago farfara L.
abstract: L-652,469, 14-acetoxy-7 beta-(3'-ethylcrotonoyloxy)-notonipetranone, isolated from the methylene chloride extracts of the buds of Tussilago farfara L, was found to inhibit both platelet activating factor (PAF) and Ca2+ entry blocker binding to membrane vesicles. It inhibits the [3H]PAF specific binding to rabbit platelet membranes with equilibrium inhibition constants (Ki) of 3.2 and 4.0 microM in the presence of 150 mM NaCl and 10 mM MgCl2 respectively. It is a competitive PAF receptor antagonist with an equilibrium dissociation constant (KB) of 5.16 microM. It also competitively inhibits the specific binding of Ca2+ channel blockers (e.g. [3H]nitrendipine; Ki = 1.2 microM) in cardiac sarcolemmal vesicles. At 10(-5) M, L-652,469 causes a 60% relaxation of Ca2+-induced contraction of rat thoracic aorta strips. Due to its dual antagonistic activities, L-652,469 potently inhibits the gel-filtered rabbit platelet aggregation with a pA2 of 5.79. It was also found to be orally active with a beneficial effect to inhibit the PAF-induced rat foot edema and the first phase of carrageenan-induced rat hindpaw edema.
authors.affiliation: Merck Sharp & Dohme Research Laboratories, Rahway, NJ 07065-0900.
authors.forename: S B
authors.initials: SB
authors.lastname: Hwang
authors.forename: M N
authors.initials: MN
authors.lastname: Chang
authors.forename: M L
authors.initials: ML
authors.lastname: Garcia
authors.forename: Q Q
authors.initials: QQ
authors.lastname: Han
authors.forename: L
authors.initials: L
authors.lastname: Huang
authors.forename: V F
authors.initials: VF
authors.lastname: King
authors.forename: G J
authors.initials: GJ
authors.lastname: Kaczorowski
authors.forename: R J
authors.initials: RJ
authors.lastname: Winquist
mesh_terms: D000818:Animals; D001792:Blood Platelets / Q000378:metabolism; D015220:Calcium Channels; D004487:Edema / Q000517:prevention & control; D066298:In Vitro Techniques; D007700:Kinetics; D010946:Plants, Medicinal; D010980:Platelet Membrane Glycoproteins; D011817:Rabbits; D051381:Rats; D011956:Receptors, Cell Surface / Q000187:drug effects* / Q000378:metabolism; D043562:Receptors, G-Protein-Coupled; D011978:Receptors, Nicotinic / Q000187:drug effects*; D012508:Sarcolemma / Q000378:metabolism; D012717:Sesquiterpenes; D013729:Terpenes / Q000302:isolation & purification / Q000494:pharmacology*; D014661:Vasoconstriction / Q000187:drug effects
chemical_list: D015220:Calcium Channels; D010980:Platelet Membrane Glycoproteins; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; D011978:Receptors, Nicotinic; D012717:Sesquiterpenes; D013729:Terpenes; C039351:platelet activating factor receptor; C054337:tussilagone